

CITATION REPORT

List of articles citing

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors

DOI: 10.1159/000335587

Neuroendocrinology, 2012, 95, 120-34.

Source: <https://exaly.com/paper-pdf/53981453/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
436	[Clinicopathologic characteristics of 127 cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) studied in an oncology hospital]. 2012 , 77, 174-80		2
435	Everolimus for the treatment of advanced pancreatic neuroendocrine tumors. 2012 , 2, 1123-1131		
434	Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. 2012 , 47, 941-60		80
433	Perspective: multimodality radionuclide therapy of progressive disseminated lymphoma and neuroendocrine tumors as a paradigm for cancer control. 2012 , 27, 525-9		1
432	Parenchyma-sparing resections for pancreatic neuroendocrine tumors. 2012 , 16, 2045-55		78
431	Pathology - grading and staging of GEP-NETs. 2012 , 26, 705-17		48
430	Neuroendocrine tumor disease: an evolving landscape. 2012 , 19, R163-85		96
429	Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. 2012 , 26, 737-53		142
428	Intervention in gastro-enteropancreatic neuroendocrine tumours. 2012 , 26, 855-65		13
427	Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review. 2012 , 2012, 357475		15
426	Neoplastic lesions of endocrine cells in the gastrointestinal tract: ten evolving principles as a basis for clinical understanding. 2012 , 1		
425	Pancreatic neuroendocrine tumours [New therapeutic concepts. 2012 , 5, 63-65		
424	Long-term outcome of laparoscopic surgery for pancreatic neuroendocrine tumors. 2013 , 37, 582-90		47
423	Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. <i>Neuroendocrinology</i> , 2013 , 97, 347-54	5.6	83
422	Pancreatic neuroendocrine tumors. 2013 , 32, 3-17		1
421	Uncommon Pancreatic Neoplasms. 2013 ,		0
420	Cystic and ductal tumors of the pancreas: diagnosis and management. 2013 , 150, 69-84		9

419	Endoscopic ultrasound (EUS)-guided fiducial placement allows localization of small neuroendocrine tumors during parenchymal-sparing pancreatic surgery. 2013 , 27, 3921-6		34
418	Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. 2013 , 40, 897-907		61
417	Aktuelle Diagnostik und Therapie von gastroenteropankreatischen neuroendokrinen Tumoren (GEP-NET). 2013 , 19, 218-223		
416	Chirurgie endokriner Tumoren des Pankreas. 2013 , 19, 224-229		0
415	Epidemiology and Clinical Presentation. 2013 , 61-69		2
414	Tumeurs kystiques et canalaire du pancreas de découverte fortuite : diagnostic et conduite à tenir. 2013 , 150, 87-103		
413	Effect of temozolomide in patients with metastatic bronchial carcinoids. <i>Neuroendocrinology</i> , 2013 , 98, 151-5	5.6	64
412	Nonfunctional pancreatic neuroendocrine tumors . 2013 , 17, 2105-13		53
411	Tumores neuroendócrinos pancreáticos: análise retrospectiva de 12 anos de experiência do Instituto Português de Oncologia de Lisboa. 2013 , 8, 2-8		
410	Pancreatic surgery with vascular reconstruction in patients with locally advanced pancreatic neuroendocrine tumors. 2013 , 17, 1224-32		22
409	Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. 2013 , 15, 935-43		11
408	Extra-appendiceal neuroendocrine neoplasms in children - data from the GPOH-MET 97 Study. 2013 , 225, 315-9		14
407	The use of biomarkers in neuroendocrine tumours. 2013 , 4, 175-181		5
406	Surgical treatment of neuroendocrine tumors (including carcinoid). 2013 , 20, 32-6		11
405	The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. 2013 , 5, 286-300		5
404	Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. 2013 , 18, 525-32		36
403	Tumeurs neuroendocrines du pancreas : diagnostic, caractérisation clinique, pronostic et traitement. 2013 , 8, 1-16		
402	Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. 2013 , 92, 135-181		141

401	Pancreatic adenocarcinoma in a patient with multiple endocrine neoplasia 1 syndrome. 2013 , 42, 725-6	3
400	International practice patterns and resource utilization in the treatment of neuroendocrine tumors. 2013 , 42, 339-47	10
399	Calcitonin-secreting pancreatic neuroendocrine tumors: a case report and review of the literature. 2014 , 20, e140-4	9
398	Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. 2014 , 37, 875-909	16
397	GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors. 2014 , 171, R153-62	22
396	Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors. 2014 , 49, 734-41	23
395	Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden. 2014 , 31, 407-14	19
394	PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. 2014 , 10, 2259-77	119
393	Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. <i>Radiology</i> , 2014 , 270, 517-25	71
392	CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms. 2014 , 21, 879-90	10
391	Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. 2014 , 80, 850-5	29
390	Outcome of surgery for pancreatic neuroendocrine neoplasms. 2014 , 101, 1405-12	83
389	Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. 2014 , 43, 526-31	38
388	RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner. 2014 , 74, 6661-70	23
387	Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up. <i>Neuroendocrinology</i> , 2014 , 99, 108-17	5.6 51
386	Clinical Applications of SPECT-CT. 2014 ,	5
385	Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections. 2014 , 90, 89-97	12
384	Pancreatic neuroendocrine tumors: current opinions on a rare, but potentially curable neoplasm. 2014 , 26, 826-35	7

383	Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome. 2014 , 218, 163-9	26
382	Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis. 2014 , 155, 13-21	53
381	A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours. 2014 , 40, 376-89	40
380	Neuroendokrine Tumoren. 2014 , 9, 36-46	
379	Clinical approach to the patient with a solid pancreatic mass. 2014 , 164, 73-9	2
378	Outcome of peptide receptor radionuclide therapy with ¹⁷⁷ Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. 2014 , 41, 925-33	138
377	Pancreastatin predicts survival in neuroendocrine tumors. 2014 , 21, 2971-80	45
376	Comment on "predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine". 2014 , 155, 582-4	1
375	When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery. 2014 , 155, 887-92	89
374	Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria. 2014 , 122, 770-8	66
373	Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by ¹⁸ F-FDG PET: feasibility of a metabolic grading system. 2014 , 55, 1260-6	60
372	Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors. 2014 , 31, 935-44	22
371	[Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy]. 2014 , 85, 731-44	2
370	[The relevance of PET/CT for the surgical management of neuroendocrine neoplasms]. 2014 , 85, 500-4	
369	Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. 2014 , 46, 9-17	18
368	Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. 2014 , 155, 145-53	67
367	[Malignant insulinoma: recommendations for workup and treatment]. 2014 , 43, 645-59	7
366	Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. 2014 , 208, 775-780	47

365	Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach. 2014 , 155, 607-14	55
364	High-dose lanreotide in the treatment of poorly differentiated pancreatic neuroendocrine carcinoma: a case report. 2014 , 7, 155-63	3
363	Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors. 2014 , 260, 1088-94	45
362	Somatostatin Receptor Scintigraphy in Management of Patients with Neuroendocrine Neoplasms. 2015 , 90-111	
361	AACE/ACE disease state clinical review: pancreatic neuroendocrine incidentalomas. 2015 , 21, 546-53	10
360	Nonfunctional Pancreatic Neuroendocrine Tumors: Advances in Diagnosis, Management, and Controversies. 2015 , 100, 1089-97	18
359	Neuroendokrine Neoplasien des gastroenteropankreatischen Systems. 2015 , 10, 410-417	1
358	Metastasized pancreatic neuroendocrine tumor in a teenage girl: a case report. 2015 , 9, 230	3
357	Somatostatin receptor subtype 2 expression and somatostatin receptor scintigraphy positivity in pancreatic serous cystadenomas. 2015 , 44, 672-4	2
356	Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place. 2015 , 262, 384-8	30
355	Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs). 2015 , 94, e983	34
354	Peptidrezeptor-Radionuklidtherapie Somatostatinrezeptor- exprimierender Tumore. 2015 , 54, 01-11	6
353	. 2015 ,	2
352	6.6 Chirurgische Therapie neuroendokriner Neoplasien des GI-Traktes. 2015 ,	
351	Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. 2015 , 5, 119-76	67
350	A Single Centre Analysis of Clinical Characteristics and Treatment of Endocrine Pancreatic Tumours. 2015 , 2015, 538948	2
349	Pancreatic Neuroendocrine Neoplasms. 2015 ,	3
348	Classification and Staging of Pancreatic Neuroendocrine Neoplasms. 2015 , 51-61	

347	Surgical Therapy of Pancreatic Neuroendocrine Neoplasms. 2015 , 185-190		
346	The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms. 2015 , 41, 423-30		17
345	Pancreatic neuroendocrine tumors: a review. 2015 , 11, 853-64		27
344	Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study. 2015 , 162, 682-9		19
343	Neuroendocrine Tumours. 2015 ,		5
342	Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases. <i>Neuroendocrinology</i> , 2015 , 102, 68-76	5.6	57
341	Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy. 2015 , 100, E1437-45		83
340	Endoscopy and Endoscopic Ultrasound in Assessing and Managing Neuroendocrine Neoplasms. 2015 , 44, 88-103		4
339	Genetics and Epigenetics of Pancreatic Neuroendocrine Tumors and Pulmonary Carcinoids. 2015 , 44, 115-38		4
338	Efficacy and cost-effectiveness of immediate surgery versus a wait-and-see strategy for sporadic nonfunctioning T1 pancreatic endocrine neoplasms. <i>Neuroendocrinology</i> , 2015 , 101, 25-34	5.6	8
337	Pancreatic Surgery. 2015 , 44, 139-48		5
336	Contrast-Enhanced Ultrasound (CEUS) of Pancreatic Cancer. 2015 , 3, 1		1
335	The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors. <i>Neuroendocrinology</i> , 2014 , 100, 293-9	5.6	44
334	Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET. 2015 , 38, 605-13		28
333	Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. 2015 , 221, 509-17		56
332	Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review. 2015 , 21 Suppl 1, S10-4		14
331	Pancreatic neuroendocrine tumors in von Hippel-Lindau disease. 2015 , 50, 1054-5		5
330	Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. 2015 , 3, 895-905		65

329	CEUS of the pancreas: Still research or the standard of care. 2015 , 84, 1644-9	22
328	Therapeutic Strategies for Advanced Pancreatic Neuroendocrine Tumors with Segmental Portal Hypertension. 2015 , 39, 1974-80	15
327	[Classification and malignant potential of pancreatic cystic tumors]. 2015 , 36, 99-112; quiz 113-4	16
326	Distal pancreatic resection for neuroendocrine tumors: is laparoscopic really better than open?. 2015 , 19, 831-40	52
325	Non-hyperfunctioning pancreatic endocrine tumors: multimodality imaging features with histopathological correlation. 2015 , 40, 2398-410	35
324	Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. 2015 , 51, 1253-62	69
323	Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. 2015 , 81, 848-56.e1	41
322	Genetics of pancreatic neuroendocrine tumors: implications for the clinic. 2015 , 9, 1407-19	31
321	Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis. 2015 , 400, 715-23	41
320	Feasibility of Radio-Guided Surgery with Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors. 2015 , 22 Suppl 3, S676-82	15
319	Nonfunctioning Pancreatic Neuroendocrine Tumors. 2015 , 275-298	
318	Biochemical Testing in Patients with Neuroendocrine Tumors. 2015 , 44, 24-39	10
317	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. 2015 , 100, 3231-44	79
316	Neuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate. 2015 , 8, 414-20	8
315	Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group. 2015 , 22, 2685-99	62
314	Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. 2015 , 50, 58-64	234
313	Pancreatic fistulae after pancreatic resections for neuroendocrine tumours compared with resections for other lesions. 2015 , 17, 38-45	25
312	Pancreatic Neuroendocrine Tumors. 2015 , 1375-1406	

311	A giant non-functioning pancreatic neuroendocrine carcinoma founded as an successfully treated with pancreatoduodenectomy. 2016 , 11, 211-213		
310	Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?. 2016 , 15, 15-22		22
309	Pancreatic Aetiology for Massive Upper Gastrointestinal Haemorrhage in Pregnancy. 2016 , 2016, 5491851		3
308	Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). 2016 , 11, e0158140		14
307	Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. 2016 , 114, 440-5		35
306	Inherited Pancreatic Endocrine Tumors. 2016 , 1-25		1
305	Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences. 2016 , 20, E139-E146		1
304	Surgical Treatment of Non-Functioning Pancreatic Neuroendocrine Tumours Based on Three Clinical Scenarios. 2016 , 94, 578-587		
303	Surgical treatment of non-functioning pancreatic neuroendocrine tumours based on three clinical scenarios. 2016 , 94, 578-587		
302	Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery. 2016 , 25, 223-8		11
301	Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours. 2016 , 43, 2072-83		27
300	The influence of somatostatin receptor scintigraphy during preoperative staging of non-functioning pancreatic neuroendocrine tumours. 2016 , 71, 537-42		4
299	Active Surveillance versus Surgery of Nonfunctioning Pancreatic Neuroendocrine Neoplasms \geq cm in MEN1 Patients. <i>Neuroendocrinology</i> , 2016 , 103, 779-86	5.6	39
298	New horizons for targeted treatment of neuroendocrine tumors. 2016 , 12, 1059-65		2
297	Differential diagnosis of small solid pancreatic lesions. 2016 , 84, 933-940		63
296	Tumor neuroendócrino pancreático com apresentaõ exuberante ã propósito de um caso. 2016 , 11, 236-239		0
295	Prognostic Factors in Resected Pancreatic Neuroendocrine Tumours: Experience in 95 Patients. 2016 , 94, 473-480		1
294	Prognostic factors in resected pancreatic neuroendocrine tumours: Experience in 95 patients. 2016 , 94, 473-80		5

293	Pancreatic Neuroendocrine Tumors. 2016 , 9, 595-617		8
292	Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. 2017 , 104, 34-41		86
291	Carbidopa-assisted F-fluorodihydroxyphenylalanine PET/CT for the localization and staging of non-functioning neuroendocrine pancreatic tumors. 2016 , 30, 659-668		11
290	Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. 2016 , 175, 361-6		33
289	Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. 2016 , 23, 759-67		87
288	Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms: Twenty-Three Cases Evaluated according to the WHO 2010 Classification. <i>Neuroendocrinology</i> , 2016 , 103, 567-77	5.6	7
287	Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. 2016 , 50, 61-67		64
286	Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. 2016 , 21, 1191-1199		95
285	Surgical Management of Pancreatic Neuroendocrine Tumors. 2016 , 96, 1447-1468		15
284	Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET). 2016 , 49, 1991-2000		15
283	Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus. 2016 , 11, 667-675		22
282	Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes. 2016 , 10, 444-450		6
281	Neuroendocrine Tumors. 2016 , 473-501		
280	Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program. 2016 , 16, 858		6
279	Hypovascular Non-functional Neuroendocrine Pancreatic Tumour: An Unusual Presentation of a Rare Tumour. 2016 , 94, 182-184		
278	Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review. 2016 , 61, 147-53		33
277	Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review. 2016 , 40, 729-48		55
276	Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review. 2016 , 98, 264-74		23

275	Histopathology of NET: Current concepts and new developments. 2016 , 30, 33-43		8
274	Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. 2016 , 114, 650-8		52
273	A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases. 2016 , 29, 108-17		18
272	Hypovascular non-functional neuroendocrine pancreatic tumour: an unusual presentation of a rare tumour. 2016 , 94, 182-4		
271	Gastrointestinal Neuroendocrine Tumors: Optimal Outcomes and Surgical Management. 2016 , 37-50		
270	[Digestive neuroendocrine tumors]. 2016 , 37, 551-60		2
269	Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. 2016 , 159, 862-71		52
268	Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. 2016 , 3, 53-66		43
267	ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2016 , 103, 153-71	5.6	712
266	Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. <i>Neuroendocrinology</i> , 2016 , 103, 806-14	5.6	38
265	Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1. 2016 , 40, 1729-36		38
264	Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm. 2016 , 142, 1299-306		7
263	Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours. 2016 , 16, 403-10		23
262	Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours. 2016 , 101, 445-52		34
261	Postoperative Outcomes of Enucleation and Standard Resections in Patients with a Pancreatic Neuroendocrine Tumor. 2016 , 40, 715-28		57
260	Pancreatic neuroendocrine tumour: Correlation of apparent diffusion coefficient or WHO classification with recurrence-free survival. 2016 , 85, 680-7		19
259	Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. 2016 , 34, 588-96		210
258	Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter study. 2016 , 159, 901-7		43

257	Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors. 2016 , 25, 171-94		21
256	Clinical Presentation and Diagnosis of Neuroendocrine Tumors. 2016 , 30, 21-48		39
255	Surgical management of neuroendocrine tumors. 2016 , 30, 93-102		22
254	Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity. <i>Neuroendocrinology</i> , 2016 , 103, 345-53	5.6	52
253	Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms. 2016 , 22, 79-85		49
252	Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy. 2017 , 17, 139-145		6
251	Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors - a systematic review and meta-analysis. 2017 , 19, 310-320		62
250	Nonfunctioning, small, incidental pancreatic neuroendocrine tumors: Results of a nonoperative approach cohort. 2017 , 95, 83-88		3
249	Surgery management for sporadic small (≤ 2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET). 2017 , 50, 567-574		23
248	Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors?. 2017 , 35, 242-253		21
247	Can MDCT or EUS features predict the histopathological grading scheme of pancreatic neuroendocrine neoplasms?. 2017 , 122, 319-326		4
246	The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature. 2017 , 96, e6062		7
245	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. 2017 , 143, 1209-1224		8
244	A simple morphological classification to estimate the malignant potential of pancreatic neuroendocrine tumors. 2017 , 52, 1140-1146		4
243	Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy. 2017 , 46, 589-594		35
242	Efficacy of radiotherapy for primary tumor in patients with unresectable pancreatic neuroendocrine tumors. 2017 , 47, 826-831		4
241	Guideline for the Management of Pancreatic Neuroendocrine Tumor. 2017 , 161-172		
240	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. 2017 , 6, 1493-1499		9

239	Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysis. 2017 , 43, 1808-1815	30
238	Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. 2017 , 46, 416-426	5
237	Nonfunctioning, Small, Incidental Pancreatic Neuroendocrine Tumors: Results of a Nonoperative Approach Cohort. 2017 , 95, 83-88	
236	Analysis of histological and immunohistochemical patterns of benign and malignant adrenocortical tumors by computerized morphometry. 2017 , 213, 815-823	1
235	Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study. 2017 , 49, 27-34	16
234	Major postoperative complications after pancreatic resection for P-NETS are not associated to earlier recurrence. 2017 , 43, 2119-2128	9
233	Pancreatic Neuroendocrine Tumors: Computed Tomography Enhancement, But Not Histological Grade, Correlates With Tumor Aggression. 2017 , 46, 1366-1372	7
232	Regional Metastatic Behavior of Nonfunctional Pancreatic Neuroendocrine Tumors: Impact of Lymph Node Positivity on Survival. 2017 , 46, 898-903	20
231	Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): Report of 5 cases and review of the literature. 2017 , 96, e6201	16
230	The future: diagnostic and imaging advances in MEN1 therapeutic approaches and management strategies. 2017 , 24, T209-T225	17
229	Are we reproducible in measurement of NET liver metastasis?. 2017 , 49, 1121-1127	4
228	Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. <i>Neuroendocrinology</i> , 2017 , 104, 1-10	5.6 63
227	Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines. 2017 , 18, 373-378	5
226	Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. 2017 , 2017, 6424812	6
225	Zollinger-Ellison Syndrome In Men1 Patients: Medical Or Surgical Treatment?. 2017 , 07,	1
224	[High grade insulinoma detected in a patient with a 5-year history of severe hypoglycemias]. 2017 , 27, 250	
223	Comparison of imaging-based and pathological dimensions in pancreatic neuroendocrine tumors. 2017 , 23, 3092-3098	5
222	Minimally invasive distal pancreatectomy for PNETs: laparoscopic or robotic approach?. 2017 , 8, 33872-33883	24

221	The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). 2018 , 39, e2-e44	346
220	Hepatobiliary and Pancreatic Cancer. 2018 ,	0
219	Fine-Needle Aspiration-Based Grading of Pancreatic Neuroendocrine Neoplasms Using Ki-67: Is Accurate WHO Grading Possible on Cytologic Material?. 2018 , 7, 154-459	11
218	Pancreatic Neuroendocrine Neoplasms: A Role of Laparoscopy in Surgical Treatment: Review. 2018 , 28, 147-152	4
217	Outcomes after endoscopic ultrasound-guided ethanol-lipiodol ablation of small pancreatic neuroendocrine tumors. 2018 , 30, 652-658	17
216	Prognostic Factors: Molecular Pathway [Oncogene (mTOR). 2018 , 127-133	
215	Pancreatic Neuroendocrine Tumors in Multiple Neoplasia Syndromes. 2018 , 961-966	
214	Nonfunctioning Pancreatic Neuroendocrine Tumors. 2018 , 967-971	
213	Medical and Nucleotide Treatment of Neuroendocrine Tumors of the Pancreas. 2018 , 972-978	
212	Interventional Radiology in the Treatment of Pancreatic Neuroendocrine Tumors. 2018 , 979-981	
211	Surgical Treatment of Endocrine Tumors. 2018 , 994-1001	
210	The diagnostic value of FNA biopsy in grading pancreatic neuroendocrine tumors. 2018 , 126, 170-178	14
209	Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos). 2018 , 87, 1481-1488	25
208	Toxicities, safeties and clinical response of dacarbazine-based chemotherapy on neuroendocrine tumors in Taiwan population. 2018 , 81, 423-428	1
207	EUS-guided reverse bevel fine-needle biopsy sampling and open tip fine-needle aspiration in solid pancreatic lesions - a prospective, comparative study. 2018 , 53, 231-237	15
206	Endoscopic ultrasound elastography of small solid pancreatic lesions: a multicenter study. 2018 , 50, 1071-1079	41
205	Endoscopic Ultrasound Features of Multiple Endocrine Neoplasia Type 1-Related versus Sporadic Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study. 2018 , 98, 112-118	4
204	Inherited Pancreatic Endocrine Tumors. 2018 , 573-597	

203	Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems. 2018 , 17, 169-175		12
202	Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?. 2018 , 59, 1-3		5
201	A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. 2018 , 267, 1148-1154		81
200	Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay. <i>Abdominal Radiology</i> , 2018 , 43, 613-619	3	14
199	Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study. 2018 , 142, 1139-1147		21
198	Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors: Who, When, and How to Treat?. 2018 , 98, 157-167		12
197	Pancreatectomy for pancreatic incidentaloma: What are the risks?. 2018 , 18, 114-121		11
196	Gastrointestinal Neuroendocrine Tumor Syndromes (GI NETS). 2018 , 597-616		
195	Role of surgery in pancreatic neuroendocrine tumor. 2018 , 7, 36-41		12
194	7 Cancer of the Pancreas. 2018 ,		
193	Pancreatic Islet Cell Tumors. 2018 , 626-634		
192	Resection Versus Chemotherapy for Metastatic Neuroendocrine Tumors of the Pancreas. 2018 , 441-457		
191	Surgery Versus Observation for Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Tumors. 2018 , 423-430		
190	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. <i>Neuroendocrinology</i> , 2018 , 107, 375-386	5.6	52
189	Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. 2018 , 47, 321-325		18
188	Surgical treatment of pNET - Experience of a "high-volume" center. 2018 , 27, 409-414		6
187	PPoma Review: Epidemiology, Aetiopathogenesis, Prognosis and Treatment. 2018 , 6,		14
186	Neuroendokrine Tumoren des Pankreas. 2018 , 189-202		

185	Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation. 2018 , 2018, 9647247		15
184	Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis. 2018 , 11, 975-982		18
183	Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. 2018 , 91, 20180108		15
182	Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors. 2018 , 118, 37-48		23
181	[Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27]. 2018 , 56, 583-681		69
180	Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances. 2019 , 26, 13-30		42
179	Implementation of Current ENETS Guidelines for Surgery of Small (≤2 cm) Pancreatic Neuroendocrine Neoplasms in the German Surgical Community: An Analysis of the Prospective DGAV StuDoQ Pancreas Registry. 2019 , 43, 175-182		21
178	A rational approach to postoperative surveillance for resected non-functional pancreatic neuro-endocrine tumours. 2019 , 19, 1000-1007		4
177	Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. <i>Cancers</i> , 2019 , 11,	6.6	18
176	[Modern sonographic imaging of abdominal neuroendocrine tumors]. 2019 , 59, 1002-1009		1
175	Endoscopic ultrasound-guided fine-needle biopsy is superior to fine-needle aspiration in assessing pancreatic neuroendocrine tumors. 2019 , 7, E1281-E1287		15
174	The best approach for sampling of pancreatic neuroendocrine tumors - EUS-FNA or EUS-FNB?. 2019 , 7, E1400-E1402		1
173	Contemporary issues in the surgical management of pancreatic neuroendocrine tumours. 2019 , 23, 37-41		
172	Evaluation and Management of Neuroendocrine Tumors of the Pancreas. 2019 , 99, 793-814		35
171	Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life. 2019 , 166, 157-163		19
170	Short-term and long-term outcomes after robot-assisted versus laparoscopic distal pancreatectomy for pancreatic neuroendocrine tumors (pNETs): a multicenter comparative study. 2019 , 404, 459-468		26
169	Editorial: Small, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors: Observation becoming standard of care?. 2019 , 166, 164-165		1
168	Surgical strategy for neuroendocrine liver metastases. 2019 , 23, 59-67		1

167	Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study. 2019 , 17, 66	10
166	PANCREATIC NEUROENDOCRINE TUMORS: SURGICAL RESECTION. 2019 , 32, e1428	6
165	Diagnostic Performance of Apparent Diffusion Coefficient for Prediction of Grading of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-analysis. 2019 , 48, 151-160	8
164	Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas. 2019 , 12, 1021-1044	12
163	Concomitant pancreatic neuroendocrine tumors in hereditary tumor syndromes: who, when and how to operate?. 2019 , 2, 48-53	2
162	Risk and Predictors of Postoperative Morbidity and Mortality After Pancreaticoduodenectomy for Pancreatic Neuroendocrine Neoplasms: A Comparative Study With Pancreatic Ductal Adenocarcinoma. 2019 , 48, 504-509	15
161	Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors. 2019 , 2, 91-99	1
160	Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association. 2019 , 21, 515-523	9
159	Current best practice in the management of neuroendocrine tumors. 2019 , 10, 2042018818804698	26
158	Hypervascular lesions of the pancreas: Think before you act. 2019 , 218, 362-367	3
157	Does attending a Delphi consensus conference impact surgeon attitudes? Survey results from the Americas HepatoPancreatoBiliary Association consensus conference on small asymptomatic pancreatic neuroendocrine tumors. 2019 , 21, 524-530	
156	Chemoprevention with Somatuline ^r Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1). 2019 , 43, 831-838	8
155	Ct radiomic features of pancreatic neuroendocrine neoplasms (panNEN) are robust against delineation uncertainty. 2019 , 57, 41-46	14
154	Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection. 2019 , 45, 755-760	10
153	Accuracy of grading pancreatic neuroendocrine neoplasms with Ki-67 index in fine-needle aspiration cellblock material. 2019 , 30, 187-193	11
152	Patterns of Recurrence after Resection for Pancreatic Neuroendocrine Tumors: Who, When, and Where?. <i>Neuroendocrinology</i> , 2019 , 108, 161-171	5.6 31
151	Recent advances in the diagnosis and management of pancreatic neuroendocrine tumours. 2019 , 10, 269-274	4
150	Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors. 2019 , 154, 40-45	23

149	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. 2019 , 45, 46-51		1
148	The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-trend and Outcome Analysis From 587 Consecutive Resections at a High-volume Institution. 2019 , 269, 725-732		35
147	Locally Recurrent Well-Differentiated Nonfunctioning Pancreatic Neuroendocrine Tumor Requiring Re-excision Including Portal Vein Resection. 2019 , 50, 324-327		
146	Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. 2020 , 271, 566-573		42
145	Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. 2020 , 25, e276-e283		29
144	Advances in the Diagnosis and Management of Nonfunctional Pancreatic Neuroendocrine Tumors. 2020 , 221-232		
143	The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. 2020 , 49, 1-33		102
142	Risk Factors for Recurrence in Pancreatic Neuroendocrine Tumor and Size as a Surrogate in Determining the Treatment Strategy: A Korean Nationwide Study. <i>Neuroendocrinology</i> , 2021 , 111, 794-804	5.6	0
141	Tumores neuroendocrinos. 2020 , 13, 1019-1028		
140	Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. <i>Neuroendocrinology</i> , 2021 , 111, 609-630	5.6	16
139	New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. <i>Abdominal Radiology</i> , 2020 , 1	3	8
138	CT-Based Radiomics Score for Distinguishing Between Grade 1 and Grade 2 Nonfunctioning Pancreatic Neuroendocrine Tumors. 2020 , 215, 852-863		10
137	The safety and efficacy of endoscopic ultrasound-guided ablation therapy for solid pancreatic tumors: a systematic review. 2020 , 55, 1121-1131		5
136	Absolute Counts of Peripheral Lymphocyte Subsets Correlate with the Progression-Free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumour Patients. 2020 , 12, 6727-6737		2
135	SIUMB recommendations for focal pancreatic lesions. 2020 , 23, 599-606		1
134	Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 Patients. <i>Neuroendocrinology</i> , 2021 , 111, 863-875	5.6	2
133	Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. 2020 , 41, 896-905		11
132	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≥ cm: Study Protocol for a Prospective Observational Study. 2020 , 7, 598438		7

131	Small pancreatic neuroendocrine tumors: Resect or enucleate?. 2021 , 222, 29-34		3
130	Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review. 2020 , 9,		13
129	Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors. 2020 , 99, e20324		4
128	Workup of Gastroenteropancreatic Neuroendocrine Tumors. 2020 , 29, 165-183		1
127	Predicting survival in non-functional pancreatic neuroendocrine tumours. 2020 , 90, 2026-2031		2
126	[Indications for the Surgical Management of Pancreatic Neuroendocrine Neoplasms]. 2020 , 145, 365-373		1
125	Update on the Surgical Treatment of Pancreatic Neuroendocrine Tumors. 2020 , 109, 42-52		10
124	Gender Differences in Multiple Endocrine Neoplasia Type 1: Implications for Screening?. 2020 , 36, 3-9		10
123	Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system. 2020 , 69, 877-887		41
122	Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group. <i>Neuroendocrinology</i> , 2021 , 111, 129-138	5.6	5
121	Update on gastroenteropancreatic neuroendocrine tumors. 2021 , 53, 171-182		7
120	Malignant potential of small pancreatic neuroendocrine neoplasm and its risk factors: A multicenter nationwide study. 2021 , 21, 208-214		4
119	The Landmark Series: Pancreatic Neuroendocrine Tumors. 2021 , 28, 1039-1049		4
118	Pancreatic Neuroendocrine Tumors. 2021 , 938-948.e4		
117	Circulating Biochemical Markers of Gastro-Entero-Pancreatic (GEP) Neuroendocrine Neoplasms (NENS). 2021 , 55-74		
116	Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms. 2021 , 11,		4
115	Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis. 2021 , 108, 811-816		4
114	Insights of Outcome after Resection of Small Nonfunctioning Neuroendocrine Pancreatic Tumors. 2021 , 2021, 6650386		

113	Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance. 2021 , 48, 4002-4015		6
112	Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center. <i>Frontiers in Endocrinology</i> , 2021 , 12, 657698 ⁵⁻⁷		1
111	Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. <i>Cancers</i> , 2021 , 13,	6.6	4
110	Clinical presentation, genotype-phenotype correlations, and outcome of pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome. 2021 , 74, 180-187		1
109	Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis. <i>Scientific Reports</i> , 2021 , 11, 10252	4.9	2
108	Focal Pancreatic Lesions: Role of Contrast-Enhanced Ultrasonography. 2021 , 11,		0
107	Diagnostic and Interventional Role of Endoscopic Ultrasonography for the Management of Pancreatic Neuroendocrine Neoplasms. 2021 , 10,		5
106	Management of Small Pancreatic Neuroendocrine Neoplasm. 2021 , 9, 19-24		
105	Nomogram for predicting survival of patients with metastatic nonfunctioning pancreatic neuroendocrine tumors: A SEER based study. 2021 , 100, e26347		1
104	Application of CT-Based Radiomics in Discriminating Pancreatic Cystadenomas From Pancreatic Neuroendocrine Tumors Using Machine Learning Methods. 2021 , 11, 606677		6
103	Commentary: Small nonfunctional pancreatic neuroendocrine tumors (NF-PNETS): Resect or enucleate ? The case for an individualized approach. 2021 , 222, 27-28		0
102	Usefulness of computed tomography during arteriography in a selective arterial calcium agent injection test for pancreatic gastrinoma: a case description. 2021 , 11, 3898-3903		
101	Contrast-Enhanced Ultrasonography Findings Correlate with Pathologic Grades of Pancreatic Neuroendocrine Tumors. 2021 , 47, 2097-2106		0
100	Neuroendocrine Tumors of the Duodenum and Ampulla of Vater. 2017 , 361-373		4
99	Neuroendocrine Tumors of the Pancreas. 2017 , 407-419		7
98	Pancreatic Neuroendocrine Tumors. 2014 , 1-29		1
97	RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. 2019 , 129, 1641-1653		17
96	Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification. 2015 , 10, e0143822		52

95	Clinical use of contrast-enhanced ultrasound beyond the liver: a focus on renal, splenic, and pancreatic applications. 2019 , 38, 278-288	10
94	Modern ultrasound imaging of pancreatic tumors. 2020 , 39, 105-113	10
93	[The role of endoscopic ultrasound in the diagnosis and therapy of gastrointestinal disorders]. 2014 , 155, 526-40	1
92	Should surgery be conducted for small nonfunctioning pancreatic neuroendocrine tumors: a systemic review. 2017 , 8, 35368-35375	9
91	A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival. 2016 , 7, 18978-83	15
90	Long non-coding RNA in pancreatic adenocarcinoma and pancreatic neuroendocrine tumors. 2017 , 30, 622-628	21
89	Update on surgical treatment of pancreatic neuroendocrine neoplasms. 2014 , 20, 13893-8	19
88	Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. 2015 , 21, 9512-25	74
87	Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. 2020 , 26, 2305-2322	22
86	Therapy for metastatic pancreatic neuroendocrine tumors. 2014 , 2, 8	14
85	Extensive multiarterial resection attending total duodenopancreatectomy and adrenalectomy for MEN-1-associated neuroendocrine carcinomas. 2012 , 4, 238-45	1
84	Non-functioning pancreatic neuroendocrine tumors: Surgery or observation?. 2017 , 9, 153-161	14
83	Surgical management of pancreatic neuroendocrine neoplasms. 2014 , 34, 1-5	6
82	Incidental nonfunctioning pancreatic neuroendocrine tumors: Contrast enhanced ultrasound features in diagnosis. 2021 ,	0
81	Laborchemische und genetische Diagnostik endokriner Tumoren des Pankreas. 2013 , 216-220	
80	Hormoninaktive endokrine Tumoren des Pankreas [Chirurgische Therapie. 2013 , 237-242	
79	Approche chirurgicale personnalisée selon l'histocytologie. 2013 , 39-56	
78	Surgical Therapy. 2013 , 109-116	

- 77 Surgery for Pancreatic Neuroendocrine Neoplasms (pNENs). **2014**, 77-90
- 76 SPECT/CT in Neuroendocrine Tumours. **2014**, 87-110 1
- 75 Endokrine Tumoren des Pankreas: Diagnostik, Klassifikation, konservative und onkologische Therapie. **2015**, 1-13
- 74 Management of Hormonal Symptoms. **2015**, 501-511
- 73 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79
- 72 Neuroendocrine tumours. 656-673
- 71 [Epidemiology of neuroendocrine neoplasms]. **2016**, 94-100
- 70 Neuroendocrine Tumor Classification Systems: Grading. **2016**, 3-19
- 69 Malignome endokriner Organe. **2017**, 909-960
- 68 EUS-FNAB and somatostatin-receptor scintigraphy enabled diagnosis and detection of multiple metastatic sites in a patient with diffuse pancreatic enlargement: A case of pancreatic neuroendocrine tumor. **2017**, 32, 843-851
- 67 Neuroendocrine Tumours. 656-673
- 66 PROGNOSTIC FACTORS OF THE EFFICACY OF ARANOZA-BASED THERAPY IN NEUROENDOCRINE NEOPLASMS. **2017**, 16, 38-46 1
- 65 Long-term Survival in Patient with Metastatic Pancreatic Neuroendocrine Tumor Treated by Variable Treatment. **2017**, 22, 141-146
- 64 A Case of Malignant Insulinoma with Uncontrolled Blood Glucose Level where a Debulking Surgery was Useful. **2018**, 79, 1088-1094
- 63 Sporadic Gastroenteropancreatic Neuroendocrine Tumors. **2018**, 53-62 1
- 62 Gastroenteropankreatische neuroendokrine Neoplasien (GEP-NET). **2018**, 503-535
- 61 Pancreatic Neuroendocrine Tumours. **2018**, 333-343
- 60 Management of Pancreatic and Duodenal Neuroendocrine Tumors. **2018**, 153-167

59	Endoscopic Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumors. 2018 , 79-90	
58	Neuroendocrine Pancreatic Tumors. 2018 , 99-109	
57	Bleeding and malignant pancreatic neuroendocrine neoplasms: A Malaysian case series. 2019 , 9, 1	
56	Neuroendocrine Tumors (Gastroenteropancreatic). 2020 , 345-381	
55	Amyloid-Rich Pancreatic Neuroendocrine Tumors: a Potential Diagnostic Pitfall in Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology (EUS-FNAC). 2021 , 32, 318-325	3
54	Second Primary Malignancies in Patients with Pancreatic Neuroendocrine Neoplasms: A Population-Based Study on Occurrence, Risk Factors, and Prognosis. 2021 , 2021, 1565089	0
53	Pancreas; Endocrine Tumors. 2020 , 10-23	
52	Management and outcomes of patients for non-functioning pancreatic neuroendocrine tumours: a multi-institutional analysis. 2021 ,	0
51	Comprehensive treatment of a functional pancreatic neuroendocrine tumor with multifocal liver metastases. 2014 , 26, 501-6	3
50	Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment. 2013 , 26, 29-36	29
49	Grading of EUS-FNA cytologic specimens from patients with pancreatic neuroendocrine neoplasms: it is time move to tissue core biopsy?. 2014 , 3, 222-5	9
48	ACTH-secreting pancreatic neuroendocrine carcinoma with ovarian and pelvic metastases causing Cushing's syndrome: a case report. 2015 , 8, 15396-401	4
47	A rare case of metastasized non-functional pancreatic neuroendocrine tumor with a good long-term survival. 2016 , 9, 369-372	
46	What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review. <i>Cancers</i> , 2021 , 13,	6.6 0
45	Enhanced computed tomography features predict pancreatic neuroendocrine neoplasm with Ki-67 index less than 5.. 2021 , 147, 110100	
44	Sporadische nicht-funktionelle pankreatische neuroendokrine Neoplasien. 2021 , 1-14	
43	Non-functional Pancreatic Neuroendocrine Tumors. 2021 , 695-709	
42	Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors.. <i>Cancers</i> , 2022 , 14,	6.6 0

41	Trends in Incidence and Survival of Patients with Pancreatic Neuroendocrine Neoplasm, 1987-2016.. 2021 , 2021, 4302675		2
40	American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence.. 2022 ,		0
39	Diagnosis and Surgical Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: A Literature Review.. 2022 , 2, 115-125		0
38	Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.. <i>Abdominal Radiology</i> , 2022 , 1	3	1
37	The Predicting Role of the Neutrophil-to-Lymphocyte Ratio for the Tumor Grade and Prognosis in Pancreatic Neuroendocrine Tumors.. 2022 , 12,		0
36	Contrast-enhanced US of the Liver and Kidney: A Problem-solving Modality.. <i>Radiology</i> , 2022 , 211347	20.5	0
35	Endoscopic ultrasound-guided side-fenestrated needle biopsy sampling is sensitive for pancreatic neuroendocrine tumors but inadequate for tumor grading: a prospective study.. <i>Scientific Reports</i> , 2022 , 12, 5971	4.9	1
34	C-reactive protein independently predicts survival in pancreatic neuroendocrine neoplasms. <i>Scientific Reports</i> , 2021 , 11, 23768	4.9	1
33	Qualitative imaging features of pancreatic neuroendocrine neoplasms predict histopathologic characteristics including tumor grade and patient outcome.. <i>Abdominal Radiology</i> , 2022 , 1	3	0
32	Ki-67 Proliferation Index in Fine Needle Aspiration to Predict the Tumor Biological Aggressiveness in Pancreatic Neuroendocrine Tumors. <i>SSRN Electronic Journal</i> ,	1	
31	I tumori neuroendocrini ben differenziati di grado 3 del pancreas: definizione e gestione clinica. <i>L Endocrinologo</i> ,	0	
30	Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 871210	5.7	0
29	Enucleation Is a Feasible Procedure for Well-Differentiated pNEN: A Matched Pair Analysis. <i>Cancers</i> , 2022 , 14, 2570	6.6	1
28	Nonfunctional pancreatic neuroendocrine tumours misdiagnosed as autoimmune pancreatitis: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 2022 , 10, 4886-4894	1.6	
27	Early detection of pancreatic tumors by advanced EUS imaging. <i>Minerva Gastroenterology</i> , 2022 , 68,	3	
26	Analysis of Prognostic Risk Factors of Endoscopic Submucosal Dissection (ESD) and Curative Resection of Gastrointestinal Neuroendocrine Neoplasms. <i>Contrast Media and Molecular Imaging</i> , 2022 , 2022, 1-7	3.2	
25	Pancreatic Neuroendocrine Tumors. 2023 , 197-217		
24	Rare Bone Metastasis of Neuroendocrine Tumors of Unknown Origin: A Case Report and Literature Review. <i>Orthopaedic Surgery</i> ,	2.5	

23	Evaluation of Risk Factors for Distant and Lymph Node Metastasis of Pancreatic Neuroendocrine Tumors. Volume 18, 745-752	
22	Whole-body tumor burden in PET/CT expert review.	0
21	Surgical Management of Pancreatic Neuroendocrine Tumors (PNET). 2022 , 711-733	0
20	Kontrastverstärkter Ultraschall des Pankreas. 2022 , 53-72	0
19	Lymph node metastases and recurrence in pancreatic neuroendocrine neoplasms. 2022 ,	0
18	Gastroenteropancreatic Neuroendocrine Tumors. 2022 , 51, 625-647	1
17	A novel tool to predict nodal metastasis in small pancreatic neuroendocrine tumors: A multicenter study. 2022 ,	0
16	Special issue The advance of solid tumor research in China Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors.	0
15	Surgical Management of Pancreatic Neuroendocrine Tumors (PNET). 2021 , 1-23	0
14	The Evolving Landscape of Neuroendocrine Tumors. 2022 ,	0
13	Sporadische nicht-funktionelle pankreatische neuroendokrine Neoplasien. 2023 , 463-475	0
12	Contrast-Enhanced Harmonic Endoscopic Ultrasound for Diagnosis of the Aggressiveness of Pancreatic Neuroendocrine Neoplasm. 2022 , 12, 2988	1
11	Evaluation of quality of clinical management of neuroendocrine tumors. 2022 , 1, 305-315	0
10	Radiomics and artificial intelligence. 2023 , 365-401	0
9	Recent progress of experimental model in pancreatic neuroendocrine tumors: drawbacks and challenges.	0
8	Management of Small Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Current Opinion and Controversies. 2023 , 12, 251	0
7	Somatostatin receptor activity assessed by 68Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic neuroendocrine tumors.	0
6	Pancreatic neuroendocrine tumors: tailoring imaging to specific clinical scenarios.	0

- 5 Preoperative acute pancreatitis and hyperenzymemia are associated with poor prognosis in patients with nonfunctional pancreatic neuroendocrine tumors. ○
- 4 Tumeurs neuroendocrines digestives bien différenciées: focus sur les tumeurs pancréatiques. **2023**, ○
- 3 Outcomes after primary tumor resection of metastatic pancreatic neuroendocrine tumors: An analysis of the National Cancer Database. ○
- 2 Role of PET gamma detection in radioguided surgery: a systematic review. ○
- 1 Approaching Small Neuroendocrine Tumors with Radiofrequency Ablation. **2023**, 13, 1561 ○